Look forward to seeing more of the read-out results. Obviously the early ones have been good. Bell Potter picked this and VLA as the best / most advanced. Should see the price move ahead as further de-risking occurs and CE gets closer. Should at least move closer to the current 12 month target prices near $0.40.
Sure will raise, but will likely be higher and there should be pretty good appetite now and another de-risking. Many failed underbidders for SRX and OSL can move into first line in liver, not just pancreas.
Add to My Watchlist
What is My Watchlist?
